Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases

Summary On-target, cell-active chemical probes are of fundamental importance in chemical and cell biology, whereas poorly characterized probes often lead to invalid conclusions. Human N-myristoyltransferase (NMT) has attracted increasing interest as target in cancer and infectious diseases. Here we report an in-depth comparison of five compounds widely applied as human NMT inhibitors, using a combination of quantitative whole-proteome N-myristoylation profiling, biochemical enzyme assays, cytotoxicity, in-cell protein synthesis, and cell-cycle assays. We find that N-myristoylation is unaffected by 2-hydroxymyristic acid (100 μM), D-NMAPPD (30 μM), or Tris-DBA palladium (10 μM), with the latter compounds causing cytotoxicity through mechanisms unrelated to NMT. In contrast, drug-like inhibitors IMP-366 (DDD85646) and IMP-1088 delivered complete and specific inhibition of N-myristoylation in a range of cell lines at 1 μM and 100 nM, respectively. This study enables the selection of appropriate on-target probes for future studies and suggests the need for reassessment of previous studies that used off-target compounds.

[1]  J. Arbiser,et al.  Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model , 2016, Oncotarget.

[2]  A. Bielawska,et al.  (1S,2R)-D-erythro-2-(N-Myristoylamino)-1-phenyl-1-propanol as an Inhibitor of Ceramidase (*) , 1996, The Journal of Biological Chemistry.

[3]  M. Dallman,et al.  Multifunctional Reagents for Quantitative Proteome-Wide Analysis of Protein Modification in Human Cells and Dynamic Profiling of Protein Lipidation During Vertebrate Development** , 2015, Angewandte Chemie.

[4]  D. Goulding,et al.  Myristoyl-CoA:Protein N-Myristoyltransferase, an Essential Enzyme and Potential Drug Target in Kinetoplastid Parasites* , 2003, The Journal of Biological Chemistry.

[5]  Edward W. Tate,et al.  Global profiling of co- and post-translationally N-myristoylated proteomes in human cells , 2014, Nature Communications.

[6]  S. Lohmann,et al.  N-terminal Myristoylation Is Required for Membrane Localization of cGMP-dependent Protein Kinase Type II (*) , 1996, The Journal of Biological Chemistry.

[7]  I. Gilbert,et al.  Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi , 2016, PLoS neglected tropical diseases.

[8]  Edward W. Tate,et al.  Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode. , 2012, Journal of medicinal chemistry.

[9]  T. Utsumi,et al.  C‐terminal 15 kDa fragment of cytoskeletal actin is posttranslationally N‐myristoylated upon caspase‐mediated cleavage and targeted to mitochondria , 2003, FEBS letters.

[10]  Ian H. Gilbert,et al.  N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.

[11]  Ian H. Gilbert,et al.  Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors , 2011, Journal of medicinal chemistry.

[12]  B. Cravatt,et al.  A Second Mammalian N-Myristoyltransferase* , 1998, The Journal of Biological Chemistry.

[13]  T. Shanafelt,et al.  Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells , 2016, Leukemia & lymphoma.

[14]  J. Arbiser,et al.  Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma , 2015, Leukemia & lymphoma.

[15]  D. Yoo,et al.  Myristoylation of the small envelope protein of porcine reproductive and respiratory syndrome virus is non-essential for virus infectivity but promotes its growth , 2009, Virus Research.

[16]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[17]  M. Wright,et al.  Protein myristoylation in health and disease , 2010, Journal of chemical biology.

[18]  J. Steyaert,et al.  Structural and genomic decoding of human and plant myristoylomes reveals a definitive recognition pattern , 2018, Nature Chemical Biology.

[19]  Edward W. Tate,et al.  N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells , 2016, ACS chemical biology.

[20]  Shaying Zhao,et al.  Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression , 2018, The Journal of Biological Chemistry.

[21]  G. C. Fu,et al.  A versatile method for Suzuki cross-coupling reactions of nitrogen heterocycles. , 2006, Angewandte Chemie.

[22]  Emmanuelle Thinon,et al.  Multifunctional protein labeling via enzymatic N-terminal tagging and elaboration by click chemistry , 2011, Nature Protocols.

[23]  G. Mills,et al.  Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance , 2015, Nature Communications.

[24]  A. Bielawska,et al.  Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. , 2017, Cancer research.

[25]  B. Perry,et al.  Tris (Dibenzylideneacetone) Dipalladium, a N-Myristoyltransferase-1 Inhibitor, Is Effective against Melanoma Growth In vitro and In vivo , 2008, Clinical Cancer Research.

[26]  Edward W. Tate,et al.  Dynamic Protein Acylation: New Substrates, Mechanisms, and Drug Targets. , 2017, Trends in biochemical sciences.

[27]  J. Gordon,et al.  Genetic and biochemical studies of protein N-myristoylation. , 1994, Annual review of biochemistry.

[28]  R. Mcilhinney,et al.  Inhibition of varicella-zoster virus replication by an inhibitor of protein myristoylation. , 1993, The Journal of general virology.

[29]  J. C. de la Torre,et al.  Myristoylation of the RING Finger Z Protein Is Essential for Arenavirus Budding , 2004, Journal of Virology.

[30]  J. Chu,et al.  Inhibition of enterovirus VP4 myristoylation is a potential antiviral strategy for hand, foot and mouth disease. , 2016, Antiviral research.

[31]  K. Klingel,et al.  Cellular N-myristoyltransferases play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity , 2018, PLoS pathogens.

[32]  A. Bielawska,et al.  Bcl‐2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes , 2002, FEBS letters.

[33]  A. A. Stepanenko,et al.  Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability. , 2015, Gene.

[34]  M. Nadler,et al.  Treatment of T cells with 2-hydroxymyristic acid inhibits the myristoylation and alters the stability of p56lck. , 1993, Biochemistry.

[35]  Edward W. Tate,et al.  Bioorthogonal chemical tagging of protein cholesterylation in living cells. , 2011, Chemical communications.

[36]  Marco Y. Hein,et al.  Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.

[37]  E. Tate,et al.  Whole Proteome Profiling of N-Myristoyltransferase Activity and Inhibition Using Sortase A. , 2019, Molecular & cellular proteomics : MCP.

[38]  Edward W. Tate,et al.  N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis , 2013, Parasitology.

[39]  Stuart P. McElroy,et al.  Lead optimization of a pyrazole sulfonamide series of trypanosoma brucei N myristoyltransferase inhibitors , 2014 .

[40]  R. Geahlen,et al.  Metabolic activation of 2-substituted derivatives of myristic acid to form potent inhibitors of myristoyl CoA:protein N-myristoyltransferase. , 1990, Biochemistry.

[41]  Edward W. Tate,et al.  Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. , 2014, Nature chemistry.

[42]  R. Owen,et al.  A new, robust, and nonradioactive approach for exploring N-myristoylation[S] , 2012, Journal of Lipid Research.

[43]  Edward W. Tate,et al.  Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei , 2016, ACS infectious diseases.

[44]  Julian Blagg,et al.  Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology , 2017, Cancer cell.

[45]  R. Geahlen,et al.  S-(2-oxopentadecyl)-CoA, a nonhydrolyzable analogue of myristoyl-CoA, is a potent inhibitor of myristoyl-CoA:protein N-myristoyltransferase. , 1989, Journal of medicinal chemistry.

[46]  Lily Yang,et al.  Palladium based nanoparticles for the treatment of advanced melanoma , 2019, Scientific Reports.

[47]  D. C. Wood,et al.  Genetic studies reveal that myristoylCoA:protein N‐myristoyltransferase is an essential enzyme in Candida albicans , 1995, Molecular microbiology.

[48]  Stuart P. McElroy,et al.  Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma bruceiN-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis , 2014, Journal of medicinal chemistry.

[49]  F. Dyda,et al.  GCN5-related N-acetyltransferases: a structural overview. , 2000, Annual review of biophysics and biomolecular structure.

[50]  S. Johnston,et al.  Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus , 2018, Nature Chemistry.